178 related articles for article (PubMed ID: 7981584)
1. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.
Klein R; Berg PA
Clin Investig; 1994 Jul; 72(7):541-9. PubMed ID: 7981584
[TBL] [Abstract][Full Text] [Related]
2. Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data.
Barth H; Berg PA; Klein R
Adv Exp Med Biol; 1999; 467():487-96. PubMed ID: 10721092
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities.
Kaufman LD; Varga J; Gomez-Reino JJ; Jimenez S; Targoff IN
Clin Immunol Immunopathol; 1995 Aug; 76(2):115-9. PubMed ID: 7542184
[TBL] [Abstract][Full Text] [Related]
4. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.
Olin R; Klein R; Berg PA
Clin Rheumatol; 1998; 17(2):89-94. PubMed ID: 9641502
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to nuclear lamin C in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion.
Varga J; Maul GG; Jimenez SA
Arthritis Rheum; 1992 Jan; 35(1):106-9. PubMed ID: 1290474
[TBL] [Abstract][Full Text] [Related]
6. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders.
Klein R; Berg PA
Eur J Med Res; 1995 Oct; 1(1):21-6. PubMed ID: 9392689
[TBL] [Abstract][Full Text] [Related]
7. [Incidence and clinical relevance of antibodies to phospholipids, serotonin and ganglioside in patients with sudden deafness and progressive inner ear hearing loss].
Heller U; Becker EW; Zenner HP; Berg PA
HNO; 1998 Jun; 46(6):583-6. PubMed ID: 9677490
[TBL] [Abstract][Full Text] [Related]
8. L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.
Barth H; Klein R; Berg PA
Clin Exp Immunol; 2001 Nov; 126(2):187-92. PubMed ID: 11703359
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome.
Werle E; Fischer HP; Müller A; Fiehn W; Eich W
J Rheumatol; 2001 Mar; 28(3):595-600. PubMed ID: 11296965
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome.
Klein R; Bänsch M; Berg PA
Psychoneuroendocrinology; 1992 Nov; 17(6):593-8. PubMed ID: 1287679
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies in patients with eosinophilia myalgia and toxic oil syndrome.
Carreira PE; Montalvo MG; Kaufman LD; Silver RM; Izquierdo M; Gomez-Reino JJ
J Rheumatol; 1997 Jan; 24(1):69-72. PubMed ID: 9002013
[TBL] [Abstract][Full Text] [Related]
12. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
Kurihara N; Yanagisawa H; Jin Z; Wada O
Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
[TBL] [Abstract][Full Text] [Related]
13. Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.
Cilursu AM; Goeken J; Olson RR
Ann Rheum Dis; 1991 Nov; 50(11):817-9. PubMed ID: 1772299
[TBL] [Abstract][Full Text] [Related]
14. L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia.
Böhme A; Wolter M; Hoelzer D
Ann Hematol; 1998 Nov; 77(5):235-8. PubMed ID: 9858150
[TBL] [Abstract][Full Text] [Related]
15. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome.
Hudson JI; Pope HG; Carter WP; Daniels SR
J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180
[TBL] [Abstract][Full Text] [Related]
16. [A case of the eosinophilia-myalgia syndrome].
Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
[TBL] [Abstract][Full Text] [Related]
17. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis.
Varga J; Jimenez SA; Uitto J
J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409
[TBL] [Abstract][Full Text] [Related]
18. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
[TBL] [Abstract][Full Text] [Related]
19. L-tryptophan-induced eosinophilia-myalgia syndrome. II. Partial correction of abnormal tryptophan metabolism by pyridoxine.
Mainetti C; Fathi M; Saurat JH
Dermatologica; 1991; 183(1):62-5. PubMed ID: 1722762
[TBL] [Abstract][Full Text] [Related]
20. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
Allen JA; Peterson A; Sufit R; Hinchcliff ME; Mahoney JM; Wood TA; Miller FW; Whitfield ML; Varga J
Arthritis Rheum; 2011 Nov; 63(11):3633-9. PubMed ID: 21702023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
